# Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy

> **NCT07162818** · PHASE4 · COMPLETED · sponsor: **Indonesia University** · enrollment: 61 (actual)

## Conditions studied

- Proliferative Vitreoretinopathy
- Rhegmatogenous Retinal Detachment

## Interventions

- **DRUG:** Nepafenac 0.1% eyedrops
- **DRUG:** Control (placebo) group

## Key facts

- **NCT ID:** NCT07162818
- **Lead sponsor:** Indonesia University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-28
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162818, "Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT07162818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*